BMS Resets 2023 Guidance With Bigger Than Expected Drop In Revlimid Sales
Pressure On New Drugs As Long-Term Guide Maintained
Bristol saw a big jump in free Revlimid and Pomalyst provided through patient support programs. It does not expect the issue to persist in 2024, but now expects 2023 revenue to decline rather than grow.
